These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 16626892)
21. Rectal-wall dose dependence on postplan timing after permanent-seed prostate brachytherapy. Taussky D; Yeung I; Williams T; Pearson S; McLean M; Pond G; Crook J Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):358-63. PubMed ID: 16563654 [TBL] [Abstract][Full Text] [Related]
22. Effect of edema on postimplant dosimetry in prostate brachytherapy using CT/MRI fusion. Tanaka O; Hayashi S; Matsuo M; Nakano M; Uno H; Ohtakara K; Miyoshi T; Deguchi T; Hoshi H Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):614-8. PubMed ID: 17869675 [TBL] [Abstract][Full Text] [Related]
23. Effect of random seed placement error in permanent transperineal prostate seed implant. Bues M; Holupka EJ; Meskell P; Kaplan ID Radiother Oncol; 2006 Apr; 79(1):70-4. PubMed ID: 16515813 [TBL] [Abstract][Full Text] [Related]
24. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558 [TBL] [Abstract][Full Text] [Related]
25. (125)I monotherapy using D90 implant doses of 180 Gy or greater. Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505 [TBL] [Abstract][Full Text] [Related]
26. Is an 192Ir permanent seed implant feasible for prostate brachytherapy? Glasgow GP; Dogan N; Mohideen N Brachytherapy; 2002; 1(4):195-203. PubMed ID: 15062167 [TBL] [Abstract][Full Text] [Related]
27. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203 [TBL] [Abstract][Full Text] [Related]
28. Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy. Crook J; Patil N; Ma C; McLean M; Borg J Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1079-84. PubMed ID: 19879700 [TBL] [Abstract][Full Text] [Related]
29. Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer. Tanaka N; Fujimoto K; Hirao Y; Asakawa I; Hasegawa M; Konishi N Urology; 2009 Aug; 74(2):407-11. PubMed ID: 19376570 [TBL] [Abstract][Full Text] [Related]
30. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Fearn PA; Kattan MW; Stock RG Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1472-7. PubMed ID: 17689026 [TBL] [Abstract][Full Text] [Related]
31. Patterns of local failure following prostate brachytherapy. Stone NN; Stock RG; White I; Unger P J Urol; 2007 May; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808 [TBL] [Abstract][Full Text] [Related]
32. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer. Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022 [TBL] [Abstract][Full Text] [Related]
33. Equivalent uniform dose, D(90), and V(100) correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer. Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Anscher MS; Oleson JR Brachytherapy; 2008; 7(2):206-11. PubMed ID: 18359669 [TBL] [Abstract][Full Text] [Related]
34. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era? Kudchadker RJ; Swanson DA; Kuban DA; Lee AK; Bruno TL; Frank SJ Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):623-7. PubMed ID: 18410998 [TBL] [Abstract][Full Text] [Related]
35. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy. Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608 [TBL] [Abstract][Full Text] [Related]
36. Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry. Ohashi T; Yorozu A; Toya K; Saito S; Momma T; Nagata H; Kosugi M Jpn J Clin Oncol; 2007 Feb; 37(2):121-6. PubMed ID: 17255159 [TBL] [Abstract][Full Text] [Related]
38. Permanent prostate brachytherapy for Japanese men: results from initial 100 patients with prostate cancer. Okaneya T; Nishizawa S; Nakayama T; Kamigaito T; Hashida I; Hosaka N Int J Urol; 2007 Jul; 14(7):602-6. PubMed ID: 17645602 [TBL] [Abstract][Full Text] [Related]
39. In vivo dosimetry with a linear MOSFET array to evaluate the urethra dose during permanent implant brachytherapy using iodine-125. Bloemen-van Gurp EJ; Haanstra BK; Murrer LH; van Gils FC; Dekker AL; Mijnheer BJ; Lambin P Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1266-72. PubMed ID: 19665317 [TBL] [Abstract][Full Text] [Related]
40. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy. Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]